Park Sung Bae, Park Seong Hoon, Kang Yun Kyung, Chung Chun Kee
Department of Neurosurgery, Seoul National University Boramae Medical Center, 5 Gil 20, Boramae-Road, Dongjak-Gu, Seoul, Korea.
Department of Radiology and the Institute for Metalbolic Disease, Wonkwang University School of Medicine, Shinyong-Dong, Iksan, Jeonbuk, Korea.
Spine J. 2014 Aug 1;14(8):1748-57. doi: 10.1016/j.spinee.2014.01.042. Epub 2014 Jan 30.
In osteoporotic patients undergoing spinal arthrodesis, the use of bisphosphonates (BPs) remains controversial with regard to bone fusion. There is no consensus about the appropriate time to give BPs to patients with osteoporosis undergoing spinal arthrodesis.
We aimed to study the effect of BPs, given at different times, on the bone response to osteoporotic spinal arthrodesis.
STUDY DESIGN/SETTING: Radiological, histologic, and molecular assessments of bone formation after the different administration time of ibandronate in an ovariectomized (OVX) rat spinal fusion model.
Female Sprague-Dawley rats (n=100) were OVX (n=80) or non-OVX operated (n=20) and randomized into five groups: non-OVX, osteoporosis, and osteoporosis with early, simultaneous, and late BP groups. Eight weeks after ovariectomy, lumbar spinal arthrodesis was performed using autologous tailbones. Animals were killed 4 and 8 weeks after arthrodesis, and bone formation was assessed by measuring bone mineral density (BMD), messenger RNA expression, manual palpation, radiological evaluation, and histomorphometry.
Compared with late administration, early administration of ibandronate increased femur BMD in OVX rats and did not hinder bone fusion. Radiological analysis showed that groups given early ibandronate had increased bone volume in the grafted site 8 weeks after surgery. Histomorphometric analysis showed that ibandronate positively affected endochondral and intramembranous ossification. In the OVX groups, ibandronate increased bone turnover to a level similar to that in the non-OVX group. These findings suggested that early administration of ibandronate did not inhibit osteogenesis, including endochondral and intramembranous ossification and fusion rate.
Our results suggest that the early administration of BPs may not hinder the bone fusion of osteoporotic patients undergoing spinal arthrodesis.
在接受脊柱融合术的骨质疏松患者中,双膦酸盐(BP)在骨融合方面的应用仍存在争议。对于接受脊柱融合术的骨质疏松患者,何时给予BP尚无共识。
我们旨在研究在不同时间给予BP对骨质疏松性脊柱融合术骨反应的影响。
研究设计/场所:在去卵巢(OVX)大鼠脊柱融合模型中,对不同给药时间后依班膦酸钠的骨形成进行放射学、组织学和分子评估。
将100只雌性Sprague-Dawley大鼠分为去卵巢组(n = 80)或假手术组(n = 20)并随机分为五组:假手术组、骨质疏松组、早期BP组、同期BP组和晚期BP组。去卵巢8周后采用自体尾骨进行腰椎脊柱融合术。融合术后4周和8周处死动物,通过测量骨密度(BMD)、信使核糖核酸表达、手动触诊、放射学评估和组织形态计量学评估骨形成情况。
与晚期给药相比,早期给予依班膦酸钠可增加OVX大鼠的股骨BMD且不阻碍骨融合。放射学分析显示,早期给予依班膦酸钠的组在术后8周移植部位骨体积增加。组织形态计量学分析显示,依班膦酸钠对软骨内成骨和膜内成骨有积极影响。在OVX组中,依班膦酸钠将骨转换率提高到与假手术组相似的水平。这些发现表明,早期给予依班膦酸钠不会抑制成骨,包括软骨内成骨、膜内成骨和融合率。
我们的结果表明,早期给予BP可能不会阻碍接受脊柱融合术的骨质疏松患者的骨融合。